# Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Study · id `cardio:ct-nct01896232` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01896232](<https://clinicaltrials.gov/study/NCT01896232>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01896232

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 683 participants.

## Technical summary

Registry record NCT01896232. Randomized; double masking; primary purpose treatment. Start 2013-08-13 (actual); primary completion 2014-11-12 (actual). Results posted on 2017-02-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 683 participants (enrolled count; ClinicalTrials.gov record NCT01896232, source copy `cardio:ctgov-nct01896232-2019-07-18`, retrieved 2026-10-26)
- Started: 2013-08-13 (actual) (ClinicalTrials.gov record NCT01896232, source copy `cardio:ctgov-nct01896232-2019-07-18`, retrieved 2026-10-26)
- Primary completion: 2014-11-12 (actual) (ClinicalTrials.gov record NCT01896232, source copy `cardio:ctgov-nct01896232-2019-07-18`, retrieved 2026-10-26)
- Completion: 2015-01-08 (actual) (ClinicalTrials.gov record NCT01896232, source copy `cardio:ctgov-nct01896232-2019-07-18`, retrieved 2026-10-26)
- Results first posted: 2017-02-08 (ClinicalTrials.gov record NCT01896232, source copy `cardio:ctgov-nct01896232-2019-07-18`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Canada; Czechia; Denmark; Estonia; France; Germany; Greece; Hungary; Italy; Latvia; Lithuania; New Zealand; Poland; Portugal; Russia; Spain; Sweden; Switzerland; Türkiye (ClinicalTrials.gov record NCT01896232, source copy `cardio:ctgov-nct01896232-2019-07-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01896232-2019-07-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
- Condition: Secondary Hyperparathyroidism
- Condition: Chronic Kidney Disease
- Intervention (Drug): Etelcalcetide
- Intervention (Drug): Cinacalcet
- Intervention (Drug): Oral Placebo
- Intervention (Drug): Intravenous Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 41707a8a700490b4b25da6e96838a44e2f2042afba9502ce62e5c24e72e10678
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
